CGC
Canopy Growth Corporation
CGC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CGC overall, supported by stronger fundamentals and lower modeled downside.
CGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
CGC's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CGC PE Valuation
CGC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CGC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$1.38 |
| Q2 2026 | -$0.47 | +$2.47 |
| Q1 2026 | -$0.60 | +$3.31 |
| Q4 2025 | -$1.25 | +$2.52 |
| Q3 2025 | -$1.91 | +$2.92 |
| Q2 2025 | -$2.94 | +$3.87 |
| Q1 2025 | -$3.91 | +$2.27 |
| Q4 2024 | -$3.77 | +$6.37 |
CGC is still losing money, but far less than before: $0.53 per share over the past year, against $53.01 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CGC on earnings quality, reporting a profit while its opponent remains loss making.
CGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $57.2M | +22% |
| Q2 2026 | $57.1M | +13% |
| Q1 2026 | $50.1M | +9.6% |
| Q4 2025 | $52.4M | -0.3% |
| Q3 2025 | $46.9M | +5.9% |
| Q2 2025 | $50.7M | +8.9% |
| Q1 2025 | $45.7M | -11% |
| Q4 2024 | $52.6M | -4.8% |
CGC's revenue is recovering but still below its 2020 peak: $57M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | -2.9 points |
| Q2 2026 | -27% | +4.1 points |
| Q1 2026 | -134% | -106 points |
| Q4 2025 | -35% | -3.5 points |
| Q3 2025 | -25% | +48 points |
| Q2 2025 | -31% | +13 points |
| Q1 2025 | -28% | +119 points |
| Q4 2024 | -32% | +45 points |
CGC's operating margin was −28% last quarter, down 2.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CGC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CGC on profitability, with a higher operating margin.
CGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.9M | +$2.6M |
| Q2 2026 | -$18.1M | -$9.9M |
| Q1 2026 | -$13.5M | +$11.9M |
| Q4 2025 | -$13.4M | +$6.4M |
| Q3 2025 | -$13.5M | +$26.2M |
| Q2 2025 | -$8.2M | +$31M |
| Q1 2025 | -$25.5M | -$9.8M |
| Q4 2024 | -$19.8M | +$3.5M |
CGC has burned cash in almost every quarter: −$56M over the past year, against −$67M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CGC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +846K shares |
| 1 year | +125% | +235M shares |
| 3 years | +770% | +374M shares |
| 5 years | +1035% | +386M shares |
CGC has 423M diluted shares, up 125% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CGC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CGC Net Leverage
CGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 6.6 | Oversold |
CGC's weekly RSI is 25 (oversold) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CGC PE vs Healthcare Sector
| Metric | CGC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CGC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.74 | 23% below |
| 20 week MA | $0.88 | 35% below |
| 50 week MA | $1.02 | 44% below |
| 100 week MA | $1.25 | 54% below |
| 200 week MA | $4.80 | 88% below |
CGC is in a downtrend: it's below all five of its weekly moving averages, and 88% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CGC on trend strength, trading above more of its moving averages.
CGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $192.1 | $258.6 | +35% |
| 2021 | $258.6 | $96.2 | -63% |
| 2022 | $96.2 | $23.3 | -76% |
| 2023 | $23.3 | $5.11 | -78% |
| 2024 | $5.11 | $2.78 | -46% |
| 2025 | $2.78 | $1.19 | -57% |
| 2026 YTD | $1.19 | $0.57 | -52% |
CGC has finished five years in a row lower, and it's down 52% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CGC on returns for 2026, with the stronger performance.